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Abstract
Background: Treatment of complex regional pain syndrome type I (CRPS-I) is subject to discussion. The purpose of this 
study was to develop multidisciplinary guidelines for treatment of CRPS-I.
Method: A multidisciplinary task force graded literature evaluating treatment effects for CRPS-I according to their 
strength of evidence, published between 1980 to June 2005. Treatment recommendations based on the literature 
findings were formulated and formally approved by all Dutch professional associations involved in CRPS-I treatment.
Results: For pain treatment, the WHO analgesic ladder is advised with the exception of strong opioids. For neuropathic 
pain, anticonvulsants and tricyclic antidepressants may be considered. For inflammatory symptoms, free-radical 
scavengers (dimethylsulphoxide or acetylcysteine) are advised. To promote peripheral blood flow, vasodilatory 
medication may be considered. Percutaneous sympathetic blockades may be used to increase blood flow in case 
vasodilatory medication has insufficient effect. To decrease functional limitations, standardised physiotherapy and 
occupational therapy are advised. To prevent the occurrence of CRPS-I after wrist fractures, vitamin C is recommended. 
Adequate perioperative analgesia, limitation of operating time, limited use of tourniquet, and use of regional 
anaesthetic techniques are recommended for secondary prevention of CRPS-I.
Conclusions: Based on the literature identified and the extent of evidence found for therapeutic interventions for 
CRPS-I, we conclude that further research is needed into each of the therapeutic modalities discussed in the guidelines.
Background
Complex Regional Pain Syndrome type I (CRPS-I) is a
condition that causes multiple problems for both patients
and practitioners, due to the large variety of available
treatment options. The IASP (International Association
for the Study of Pain) definition of the syndrome reads as
follows: "CRPS Type I is a syndrome that usually develops
after an initiating noxious event, is not limited to the dis-
tribution of a single peripheral nerve, and is apparently
disproportioned to the inciting event. It is associated at
some point with evidence of oedema, changes in skin blood
flow, abnormal sudomotor activity in the region of the
pain, or allodynia or hyperalgesia" [1].
A distinction was made between CRPS type I, formerly
known as reflex sympathetic dystrophy (RSD), and type
II, where a nerve lesion can be detected (formerly known
as causalgia) [1,2].
The condition often starts in an arm or leg, and is char-
acterized by a combination of autonomic, sensory and
vasomotor symptoms. Pain, temperature asymmetry
impaired movement, change in skin colour, hyperaesthe-
sia, hyperalgesia, hyperpathy, tremor, involuntary move-
ments, muscle spasms, paresis, pseudoparalysis, skin,
muscle and bone atrophy, hyperhidrosis and changes in
hair and nail growth have been reported in patients with
this syndrome [3]. It usually requires long-term, intensive
medical therapy whereby many CRPS-I patients are no
longer able to perform their usual (social) role in every-
day life. As a result, CRPS-I has a major impact on quality
of life [4,5].
Various sets of diagnostic criteria are used side by side,
and many different therapies have been applied to this
patient group. The complexity of this problem, the fact
that various disciplines are involved in treatment, and the
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mean that a clear, uniform set of guidelines is essential. In
the light of the foregoing considerations, a multidisci-
plinary task force was instigated by the Dutch Society of
Rehabilitation Specialists and the Dutch Society of
Anaesthesiologists in order to draw up evidence-based
guidelines for CRPS-I treatment.
Methods
A multidisciplinary task force was set up in the autumn of
2003. The task force included representatives of all medi-
cal and paramedical disciplines engaged in diagnosing
and treating patients with CRPS-I, epidemiologists, a
representative of the Dutch Association of Posttraumatic
Dystrophy Patients and the Dutch Institute for Health-
care Improvement CBO. An even spread between geo-
graphical locations, balanced representation of the
various societies and bodies involved, and a fair division
between members with an academic background and
those from a non-academic background was ensured.
Members of the task force were further subdivided into
project groups addressing specific areas of CRPS treat-
ment. Relevant articles written in English, German,
French, Italian or Dutch were identified by searches in the
Cochrane Library, Medline, Embase, Cinahl and
Psychinfo, using a search string based on the PICO
method (see additional file 1). Reference lists of articles
identified were screened for relevant articles that did not
come up in the database search, and recent guidelines
were consulted. Studies were selected based on their
methodological strength (meta-analyses, systematic
reviews, randomized controlled trials (RCT's) and con-
trolled trials (CT's)). Systematic reviews and meta-analy-
ses, considered to have the highest evidential strength,
were given precedence over individual articles included
in the review. In case these studies were not available,
comparative cohort studies, comparative patient control
trials or non-comparative trials were used in the evalua-
tions. Other important criteria were: adequate size, ade-
quate follow-up, adequate exclusion of selection bias, and
whether the results obtained can be generalized to the
Dutch health care system. The search covered the period
from 1980 to June 2005, although some studies published
prior to or after this period were also used for the guide-
lines.
The members of the project group assessed the quality
of these studies on the basis of evidence-based guideline
development (EBGD) assessment forms. The studies
were then graded according to their strength of evidence
as described in table 1. Conclusions were formulated
based on the available strength of evidence, and
described in terms in accordance with the levels shown in
table 1. These descriptions ranged from clear statements
about efficacy ("It is proven that...") for level one down to
expressions of expert opinion ("The task force is of the
opinion that...") for level four conclusions.
The project group members produced texts, either
individually or in subgroups. These texts comprised
background information with respect to the intervention
and studies assessed, conclusions regarding the efficacy
of the intervention according to strength of evidence and
additional considerations concerning treatment related
issues (i.e. availability of treatment methods, side effects,
cost-effect benefits, consequences for organization of
care etc.). All texts including recommendation were dis-
cussed at plenary meetings and approved after comments
had been taken into account. The plenary project group
met ten times to discuss draft texts. The draft guidelines
were sent for external review to the participating profes-
sional societies (see acknowledgements for details) and
Table 1: Classification of the literature consulted, 
according to strength of evidence
Level of evidence for studies on intervention:
A1 systematic reviews that 
comprise at least several A2 
quality trials whose results 
are consistent
A2 high-quality randomized 
comparative clinical trials 
(randomized, double-blind 
controlled trials) of sufficient 
size and consistency
B randomized clinical trials of 
moderate quality or 
insufficient size, or other 
comparative trials (non-
randomized, comparative 
cohort study, patient control 
study)
C non-comparative trials
D opinions of experts, such 
as project group 
members
Level of evidence for conclusions:
1 at least one systematic 
review (A1) or two 
independent grade A2 
studies
2 at least two independent 
grade B studies
3 at least one grade A2, B or C 
study
4 opinions of experts, such as 
project group members
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ing. Once all comments had been taken into account, the
guidelines were adopted by the full project group and
sent to the participating professional organisations for
final approval. Formal endorsement was obtained in
December 2006.
The conclusions for each treatment modality including
strength of evidence and underlying literature will be pre-
sented in italics in the result section. The final recom-
mendations for the different treatment modalities will be
described at the end of this article. A practical algorithm
based on these guidelines is presented in additional file 2.
Results
Database and cited reference search revealed 94 relevant
studies after selection. These included 25 studies on oral
or topical drug interventions, 42 studies on invasive treat-
ments, 15 on paramedical interventions, 4 on primary
and 8 on secondary prevention of CRPS. Treatment inter-
ventions for children with CRPS, comprising 8 studies
were described separately.
Drug treatment
Pain medication
Although analgesics are often used when treating patients
with CRPS-I, and their use is described in various treat-
ment protocols and guidelines [6-8], the scientific sup-
port for their administration to patients with CRPS-I is
very limited.
Paracetamol
The use of paracetamol is described in the context of an
adjuvant pain protocol in a study into the efficacy of free
radical scavengers in treating CRPS-I (n = 146) [9]. No
studies were found evaluating paracetamol as a stand-
alone treatment for CRPS-I.
There is no evidence that paracetamol is effective in
treating pain in CRPS-I patients (level 4).
NSAIDs
Sixty-one CRPS-I patients were retrospectively evaluated
with respect to the effects of 60 mg of keterolac adminis-
tered by means of a regional intravenous blockade [10].
Twenty-six percent of patients had a complete response,
42% had a partial response and 31% had no response.
Patients with allodynia had significantly less response to
the treatment. Conflicting data have been published with
regard to the use of NSAIDs in patients with neuropathic
pain [11].
There is insufficient evidence of the degree of pain con-
trol achieved by NSAIDs in CRPS-I patients (level 3:Con-
nelly et al. (C)).
Opioids
One placebo-controlled RCT (n = 43) was found investi-
gating the effects of sustained-release oral morphine on
patients who had previously been treated with epidural
spinal cord electrical stimulation (ESES) [12]. No signifi-
cant differences were found between the extent of pain
reduction and the average time for ESES to become effec-
tive. On average, the morphine group reported 20 side-
effects a day, against 2 a day in the placebo group. An
uncontrolled study with 9 CRPS I and II patients evalu-
ated the effects of continuous infusion of morphine in the
axillary plexus following stellate blockade [13]. Signifi-
cant pain reduction at rest and at movement and
increased grip strength were found. However, the steady-
state morphine concentrations were lower than the mini-
mally effective analgesic concentration. There is little
information on weak and strong acting opioids in patients
with CRPS-I. Systematic reviews on their use for neuro-
pathic pain have found tramadol to be effective [14]. Pos-
itive short-term effects have also been reported for strong
acting opioids administered for neuropathic and muscu-
loskeletal pain [15].
There is insufficient evidence for the effects of oral opi-
oids in CRPS-I patients on pain (level 3: Harke et al. (B)).
There is insufficient evidence for the effects of infusion of
morphine to the axillary plexus on pain in CRPS-I
patients (level 3: Azad et al. (C)).
Local anaesthetics
One quasi-experimental study with 7 patients evaluated
the effects of lumbar and stellate blockades with lido-
caine/bupivacaine compared to placebo (follow up 2-2,5
weeks). No significant differences were found between
active and placebo treatment with respect to initial peak
pain reduction [16].
An uncontrolled open study investigated the long term
effects (mean follow up 32 months, range 7-48 months)
of epidural administration of bupivacaine to 14 patients
with CRPS-I in the knee [17]. Treatment was continued
with continuous administration of a narcotic. No pain
control data were described, however, 11 patients were
seen to have a complete improvement of CRPS-I symp-
toms at the end of the follow-up.
There is insufficient evidence to allow any statement
about the efficacy of local anaesthetics administered to the
sympathetic ganglia in CRPS-I patients (level 3: Price et
al. (B), Azad et al (C)).
There is insufficient evidence to allow any statement
about the efficacy of epidural administered local anaes-
thetic to CRPS-I patients. Due to use of different interven-
tions the efficacy of epidural administration of local
anaesthetics cannot be determined (level 3: Cooper et al.
(C)).
Anaesthetics
The effects of a sub-anaesthetic ketamine infusion (10
mg/hour up to 15-50 mg/hour) was assessed in a retro-
spective study of 33 patients with CRPS-I or -II [18].
Twelve patients experienced a relapse and had a second
course of infusions, three patients had a third course, by
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The average duration of pain reduction (data of 20
patients) was 9.4 months. The side-effects were intoxica-
tion, hallucinations, dizziness, nausea, light-headedness
and blurred vision.
There are indications that intravenous administration
of a sub-anaesthetic dose of ketamine reduces pain in
CRPS-I patients (level 3: Correll et al. (C)).
Anticonvulsants
Two placebo-controlled, randomized studies have been
found that examined the use of gabapentin in neuro-
pathic pain patients. The first study [19] (n = 307) shows
that gabapentin causes a modest but significant reduction
in neuropathic pain symptoms eight weeks after the start
of treatment. It is unclear what this means for the CRPS-I
patients, who made up 28% of the sample population.
In the second study (n = 58) a moderate effect on pain
was found, but no significant reductions in other sensory
abnormalities were found [20]. Dizziness, sleepiness and
fatigue occurred significantly more often in patients tak-
ing gabapentin than in patients taking placebo.
There are indications that gabapentin administered at
doses of 600 to 1800 mg every 24 hours in the first eight
weeks can cause some reduction in pain symptoms suf-
fered by patients with CRPS-I.
There is limited evidence that gabapentin reduces sen-
sory abnormalities such as hyperaesthesia and allodynia.
The long-term effect of gabapentin on patients with CRPS-
I is not known (level 2: Serpell (B), Van de Vusse et al. (B)).
No studies were found evaluating the effects for other
anticonvulsants in relation to CRPS I.
There is no evidence that anticonvulsants such as car-
bamazepine, pregabalin and phenytoin are effective in
reducing pain in CRPS-I patients (level 4).
Antidepressants
No studies testing tricyclic antidepressants on patients
with CRPS-I were available.
There is no evidence that antidepressants are effective in
reducing pain in patients with CRPS-I (level 4).
Capsaicin
Only one study has been found in which an extremely
high dose of capsaicin (5 to 10%) was administered to ten
patients with CRPS-I [21]. Doses of this strength can only
be spread onto patients' skin if the painful body part is
first numbed by epidural anaesthesia.
The investigators claim to have succeeded in 90% of
patients in achieving pain reduction. No scientific con-
clusions can yet be drawn from this open-label study.
There is insufficient evidence that capsaicin is effective
in CRPS-I patients (level 4)
Free radical scavengers
A prospective crossover study [22] with 20 patients found
a positive effect of dimethylsulphoxide (DMSO) on the
function of the affected limb. In 26 CRPS-I patients
DMSO was found to be significantly more effective than
the conventional regional ismelin block [23] in reducing
pain. A randomised double-blind trial conducted with 32
CRPS-I patients [24] showed that 5 times daily use of
DMSO in cremor vaselini cetomacrogolis provided sig-
nificantly better results on CRPS-I symptoms than pla-
cebo after two months of treatment. A randomized
double-blind study in 146 CRPS-I patients found compa-
rable results for DMSO cream and N-acetylcysteine [9].
In general, DMSO generates lower (direct and indirect)
costs than N-acetylcysteine. Subgroup analysis indicates
that N-acetylcysteine is more cost effective in patients
with a cold form of CRPS-I than DMSO. The opposite
holds for warm forms of CRPS-I [25].
DMSO (dimethylsulphoxide) cream (50%) reduces the
symptoms of CRPS-I patients (level 2: Perez et al (A2),
Geertzen et al. (B); Goris et al. (B), Zuurmond et al. (B)).
It is likely that 600 mg of N-acetylcysteine administered
three times a day reduces the symptoms of CRPS-I (level 3:
Perez et al. (A2)).
There are indications that 50% DMSO (dimethylsul-
phoxide) cream is more effective on primary warm CRPS-I
while N-acetylcysteine (NAC) is more effective on primary
cold CRPS-I (level 3: Perez et al. (C)).
Oral muscle relaxants
Motor symptoms of CRPS-I may include paresis, dysto-
nia, myoclonias and/or tremor. Five descriptive studies
have been conducted into movement disorders in CRPS-I
patients (n = 5-43) [26-30]. Three of these studies
reported that a small number of CRPS-I patients with
dystonia/spasms did benefit from treatment with benzo-
diazepines and high doses of baclofen [28]. No controlled
studies have been carried out on the treatment of either
dystonia or spasms in patients with CRPS-I. Two descrip-
tive studies report that anticholinergics have never pro-
duced (lasting) effects [29,30].
There is insufficient evidence of the efficacy of muscle
relaxants in treating movement disorders associated with
CRPS-I, such as dystonia and muscle spasms (level 3:
Bathia et al. (C), Van Hilten et al. (C), Jankovic et al. (C),
Marsden et al. (C), Schwartzman et al. (C)).
Botulin toxin
One study described the use of botulin toxin A to treat 14
patients with very severe tonic dystonia of the hand
('clenched fist') [31]. In four of these patients, the dysto-
nia developed in the context of CRPS-I. An 'overall'
improvement in pain and muscle relaxation was achieved
in four out of five hands, but the extent of improvement
was not described. Other articles report that botulin
toxin injections never work, or only work for a short
period, and rarely lead to improvement in functionality
[27,29].
There is insufficient evidence that botulin toxin A is
effective in treating dystonia in CRPS-I patients (level 3:
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Intrathecal baclofen administration
Intrathecal baclofen therapy (ITB) is an invasive tech-
nique that has only been investigated in two patients with
CRPS-I alone [32] and seven CRPS-I-dystonia patients
[33] whose condition had failed to respond to previous
treatment. Only the latter study was preceded by a dou-
ble-blind placebo-controlled crossover screening proce-
dure aimed to ascertain whether patients would be
suitable for having a programmable pump for ITB fitted.
Comparison with a placebo revealed that baclofen signifi-
cantly improved outcomes. Six patients underwent the
implant procedure and were monitored for 1.7 years as
part of an open trial with varying degrees of success.
Zuniga et al. also reported an open trial with ITB on two
CRPS-I patients with no motor disorder [32]. Pain, allo-
dynia and autonomic disorders responded well to ITB.
The main side-effects of the screening process and con-
tinuous administration of ITB are post-puncture head-
ache, diminished consciousness and urine retention [33].
There is insufficient evidence that intrathecal baclofen
(ITB) is effective in treating dystonia in CRPS-I patients
(level 3: Van Hilten et al. (C), Zuniga et al. (C)).
Corticosteroids
Corticosteroids have been used in open trials (n = 64-69)
[34,35] and in one controlled trial (n = 23) [36] to treat
CRPS-I, all of limited methodological quality. All the
studies found corticosteroids to have a very pronounced
beneficial effect.
Corticosteroids may have a positive effect on CRPS-I.
Little is known as to the duration and dosage (level 3:
Christensen et al. (C), Grundberg et al. (C), Kozin et al.
(C)).
Calcitonin
The effects of calcitonin have been evaluated in two
meta-analyses and two systematic reviews. The meta-
analysis carried out by Kingery et al. [37] reports conflict-
ing findings as to the effects of calcitonin. The systematic
review conducted by Van den Berg et al. [38] finds no evi-
dence that calcitonin is effective in cases of CRPS-I. In
contrast, the meta-analysis carried out by Perez et al.
points to calcitonin having a positive effect on pain on
average [39], and the review carried out by Forouzanfar et
al. also describes positive results for calcium-regulating
drugs (including calcitonin) administered to CRPS-I
patients [40].
There is conflicting evidence with respect to the efficacy
of calcitonin for treatment of CRPS-I (level 1: Van den
Berg et al. (A1), Forouzanfar et al. (A1), Kingery (A1),
Perez et al. (A1)).
Bisphosphonates
Three placebo-controlled studies have been carried out
to date [40-43]. One study (n = 20) involved administra-
tion of alendronate three days in a row [41]. Another
study evaluated the efficacy of clodronate (n = 32) [42]. In
a third study, treatment comprised alendronate (40 mg:
this dose is four times as high as that given for osteoporo-
sis) administered to 40 CRPS-I patients [43]. In the three
studies, the parameters in the group of patients treated
with bisphosphonates improved significantly more than
in the placebo group.
Bisphosphonates have a beneficial effect on the signs of
inflammation in patients with CRPS-I. At present little is
known as to the optimum dosage, frequency and duration
of treatment (level 1: Forouzanfar et al. (A1), Manincourt
et al. (A2)).
Calcium-channel blockers
Two studies of moderate quality and size investigated the
effect of nifedipine and phenoxybenzamine in treating
CRPS-I [44,45]. One retrospective study with 59 patients
reports that nifedipine (20 mg per day) or phenoxyben-
zamine (up to 120 mg/day) are most effective for CRPS-I
in the acute phase [44]. Both studies are primarily
descriptive and the outcomes are subjective, failing to
describe the nature of the improvement in patients' con-
ditions.
There are indications that calcium-channel blockers
have some effect in the acute phase of CRPS-I. While they
improve blood circulation, they also cause side-effects such
as a drop in blood pressure and headache (level 3: Muize-
laar et al. (C), Prough et al. (C)).
Invasive treatment
Intravenous sympathetic blockade
Eight studies have been carried out into the effects of
intravenous guanethidine on CRPS-I [23,46-52]. The
doses administered ranged from 10 to 30 mg. Four of
these studies (n = 9-60) were randomized, comparing
guanethidine to a placebo (in most cases 0.9% NaCl)
[46,48,50,52]. The remaining studies (n = 20-55) examin-
ing the effect of guanethidine report a temporary effect in
approximately one-third of patients.
Three additional studies were very small (n = 5-7) from
which no conclusions can be drawn [53-55]. One study (n
= 16) described a temporary effect of intravenous lido-
caine on mechanical and thermal allodynia [56]. Intrave-
nous blockades brought about by guanethidine, lidocaine,
clonidine, droperidol and reserpine have been investi-
gated in two meta-analyses and one systematic review
[37,39,40], which provided no evidence in favour of intra-
venous sympathetic blockades.
Intravenous sympathetic blockade has no added value
(pain reduction) compared to placebo in CRPS-I patients
(level 1: Kingery (A1), Forouzanfar et al. (A1), Perez et al.
(A1)).
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A number of intravenous drugs have been tested for effi-
cacy. Intravenous regional blockades produced by bretyl-
ium and ketanserine were found to achieve a significant
reduction in pain in the treatment group [57,58]. Ketan-
serine (n = 16; 10 mg for upper extremity and 20 mg for
lower extremtity administration), and two intravenous
applications of bretylium at 1.5 mg/kg with lidocaine (in
12 patients) provided slight pain relief. Intravenous
administration of reserpine, droperidol and atropine had
no effect [37].
There are indications that 10-20 mg of ketanserine
administered by intravenous injection reduces pain in
CRPS-I patients. Reserpine, droperidol and atropine do
not relieve pain in CRPS-I patients (level 1: Kingery (A1),
Hanna et al. (B), Hord et al. (B)).
Percutaneous sympathetic blockade
The literature contains one systematic review of the ther-
apeutic role of local anaesthetic sympathetic blockades in
patients with CRPS-I [59]. That review assessed 29 stud-
ies performed on 1144 patients with CRPS-I, and con-
cludes that critical examination of the studies raises the
question of whether sympathetic blockade is of any bene-
fit at all in CRPS-I. Less than a third of the patients
reported temporary relief of pain symptoms following a
sympathetic blockade. However, it is unclear whether this
is due to a placebo effect.
Routine administration of percutaneous sympathetic
blockade in patients with CRPS-I is not useful (level 2:
Cepeda et al. (A1)).
Surgical sympathectomy
The efficacy of surgical sympathectomy was addressed in
a systematic review [60], based on analysis of retrospec-
tive cohort including 7 to 73 individuals [61-65]. All the
studies report a clear reduction in pain due to sympath-
ectomy, whereby the extent of pain relief declines over
time. Long term follow up studies (> one year) indicate
that the chance of success is greatest if treatment is given
within three months after the initial trauma [62,63,65].
There are indications that surgical sympathectomy can
relieve pain in CRPS-I (level 3: AbuRahma et al. (C), Ban-
dyk et al. (C), Bosco Vieira Duarte (C), Mailis et al. (C),
Schwartzman et al. (C), Singh et al. (C)).
Spinal cord stimulation
Patients with chronic refractory CRPS-I were randomly
allocated to spinal cord stimulation (SCS) plus physio-
therapy or physiotherapy alone. Trial stimulation proved
successful in 24 of the 36 patients; only these patients
underwent a procedure to implant a permanent SCS
device. Pain intensity reduced by 2.4 cm on a visual ana-
logue scale after six months in the group receiving spinal
cord stimulation plus physiotherapy compared to a group
receiving only physiotherapy [66]. At two years follow-up,
pain decrease in the SCS group was 2.1 cm more than
pain decrease observed in the physiotherapy group [67].
Quality of life improved only in the patients with an
implanted system; function remained unchanged. Nine of
the 24 patients with an implanted system (38%) experi-
enced complications requiring further surgery within two
years [66,67].
Two retrospective cohort studies have investigated
effects of SCS on pain relief (n = 23-31) [68,69]. All stud-
ies relate to carefully selected patients with refractory
CRPS-I. There is no scientific evidence for SCS being
effective in non-chronic CRPS-I. Complications requir-
ing further surgery do occur in 25-50% of patients [70].
Spinal cord stimulation administered to CRPS-I
patients who are carefully selected and undergo successful
trial stimulation causes long-term pain reduction and
improves quality of life, but does not improve function
(level 3: Kemler et al. (A2), Calvillo et al. (C), Kemler et al.
(C), Kemler et al. (C)).
Amputation
Amputation is sometimes performed with the aim to
improve quality of life of CRPS I patients with severe
complications, such as threatening sepsis or severe func-
tional impairment.
Two retrospective studies [60,71] evaluating CRPS I
patients undergoing amputation were found. One study
evaluating seven patients with upper-limb CRPS-I [71],
reported three satisfied, two indecisive and two unsatis-
fied patients. In another study, 34 amputations were car-
ried out on 28 patients [72] due to pain, recurrent
infections and functional impairment. Two patients were
pain-free; ten infections were adequately controlled, and
functional improvement was achieved in nine cases.
CRPS-I relapse occurred in 28 cases, but 24 patients
remained satisfied with their amputation.
There is insufficient evidence that amputation positively
contributes to the treatment of CRPS-I (level 3: Dielissen
et al. (C), Stam et al. (C)).
Paramedical interventions
Physiotherapy
Published articles often recommend 'physiotherapy' as
adjuvant treatment, without specifying exactly what this
physiotherapy involves. In general, it is emphasized that
functional recovery is essential and forms the key to
recovery.
A randomized controlled trial (n = 135) showed that
physiotherapy given in addition to medical treatment has
a clinically relevant effect on the severity of functional
impairments [73,74]. Physiotherapy contributes primarily
to quicker reduction of pain, abnormal skin temperature,
reduced mobility and oedema. In view of the rapid
improvement of disorders it is recommended that physio-
therapy should be started at an early stage, or soon after
the diagnosis is made [73-75], and may be beneficial for
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for Mirror therapy (n = 8-13) in reducing pain [78,79].
Standardized pain-contingent physiotherapy aimed at
improving patients' ability to cope with the condition has
proven to be effective in reducing CRPS symptoms
[73,74,80].
Physiotherapy for upper-limb CRPS-I is likely to have a
beneficial impact on the disorders and on how patients
cope with the condition (level 2: Oerlemans et al. (A2),
McGabe et al. (B), Fialka et al (C)).
There are indications that physiotherapy treatment may
be beneficial for chronic CRPS-I (level 3: Moseley (B); Van
Wilgen et al. (D)).
Physiotherapy should form a part of the standard treat-
ment of CRPS-I (level 4).
Transcutaneous Electrical Nerve Stimulation (TENS)
Articles of limited methodological quality were found
describing beneficial effects of TENS in small groups of
CRPS-I (n = 10-11) patients [81,82].
There is insufficient evidence that TENS is effective in
the treatment of CRPS-I (level 4).
Occupational therapy
We found one RCT evaluating the efficacy of occupa-
tional therapy in CRPS-I (n = 135) [74]. Occupational
therapy provided in addition to medical treatment had a
positive effect on the severity of the functional limita-
tions, and appeared to have a positive impact on activity
level [73,74].
Occupational therapy has a positive effect on functional
limitations, and is likely to have a positive effect on the
activity level of patients with upper-limb CRPS-I (level 3:
Oerlemans et al. (A2)).
Rehabilitation medicine
Though no studies have been carried out to date evaluat-
ing the efficacy of integrated and coordinated multidisci-
plinary interventions for CRPS-I, experts argue for a
multidisciplinary approach because of the complex
nature of the condition, the possibility of a multifactorial
cause, and the varying nature of its progress [6,83].
There is no evidence that multidisciplinary treatment is
beneficial for CRPS-I patients (level 4: Stanton-Hicks et al.
(D), Rho et al. (D)).
Psychological treatment
It has been suggested that CRPS-I might be caused or
worsened and maintained by non-organic factors [23,84].
We found one RCT (n = 28) evaluating cognitive behav-
ioural therapy in children with CRPS-I [85]. Retrospec-
tive cohort surveys or cross-sectional studies with no
control group and limited follow-up are common. No sci-
entific publications of psychological treatments adminis-
tered to adults were found.
Treatment of children with CRPS I
Drug and invasive treatment in children
Little research has been published on specific drug or
invasive treatments for children with CRPS-I. Most of the
information is limited to descriptions of multimodal
treatments [86,87], with the use of analgesics only men-
tioned in passing.
In a case study of limited quality, 13 children with
CRPS-I (9-16 years old) [88] were evaluated to assess the
effect of home administration of continuous peripheral
nerve blockade (ropivacaine) combined with intensive
physiotherapy. The continuous analgesia was assessed as
excellent, with the motor block lasting for a limited time
(12 hours). The children were able to walk within 24
hours, and none of them showed signs of CRPS-I two
months later.
A case study of limited quality [89] examined continu-
ous intravenous infusions of carbacyclin derivatives
administered over three days combined with physiother-
apy and psychological consultation. All 7 children with
CRPS-I (aged between 6 and 11) were reported to be
symptom-free after a follow-up period of 30 months on
average (range: 25 to 37 months). Repeated infusion was
necessary in two cases.
There is insufficient data to allow any conclusions to be
drawn as to the effects of continuous peripheral nerve
blockade by means of ropivacaine or continuous intrave-
nous infusion with a carbacyclin derivative in children
with CRPS-I (level 3: Dadure et al. (C), Petje et al. (C)).
Physiotherapy for children with CRPS-I
No well-designed trials have been carried out evaluating
the effects of physiotherapy modalities in children with
CRPS-I. Between 47 and 93% of patients (n = 10-46) are
reported to recover after physical therapy [86,90]. Physio-
therapy (n = 23) given once a week for six weeks appears
to have the same effect as physiotherapy given three
times a week for six weeks [85].
The number of children experiencing one or more
relapses after treatment ranges from 10 to 48% (n = 10-
103) [81,91-93].
There are indications that physiotherapy is helpful for
children with CRPS-I. It is not clear which elements of
physiotherapy are effective, as different forms of treatment
are combined (level 3: Lee et al. (B), Barbier et al. (C), Kes-
ler et al. (C), Maillard et al. (C), Murray et al. (C), Sherry
et al. (C), Wesdock et al. (C), Wilder et al. (C)).
There are indications that children with CRPS-I may
relapse after receiving physiotherapy (10-48%) (level 3:Lee
et al. (B), Barbier et al. (C), Kesler et al. (C), Maillard et al.
(C), Murray et al. (C), Sherry et al. (C), Wesdock et al. (C),
Wilder et al. (C)).
Occupational therapy of children
An intensive treatment program (n = 23-103), comprising
occupational therapy, physiotherapy and hydrotherapy,
has been reported to be effective [87,92]. No conclusions
can be drawn from the existing literature about children
with CRPS-I with regard to the efficacy of occupational
therapy.
There are indications that occupational therapy can be
beneficial as part of a multidisciplinary approach to treat
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al. (C)).
Psychological treatment of CRPS-I in children
Relaxation therapy and biofeedback (described as cogni-
tive behavioural therapy) in combination with physio-
therapy has been evaluated for treatment of children with
CRPS-I (n = 23) [85]. Relaxation therapy and biofeedback
were reported to reduce both pain symptoms and physi-
cal function in 57% of cases (n = 72) [91]. It is not possible
to ascertain which of the three treatments contributed
most to the effects.
No conclusions can be drawn as to the effect of cognitive
behavioural therapy on children with CRPS-I (level 2: Lee
et al. (B), Wilder et al. (B), Sherry et al. (C)).
Prevention of CRPS-I
Primary prevention
Vitamin C In a randomized double-blind trial (n = 123),
patients with a wrist fracture treated with a plaster cast
were referred for treatment with vitamin C (500 mg/day
for 50 days) or a placebo. Seven percent of patients in the
group taking vitamin C developed CRPS-I, as against 22%
of patients in the control group (absolute risk reduction
15%, and number needed to treat 7) [94].
In a cohort study with a historic control group (n = 95),
patients with wrist fractures treated by surgery were
given vitamin C (1000 mg/day for 45 days). Two percent
of patients in the group treated with vitamin C developed
CPRS-I, compared to 10% in the control group [95].
It is likely that oral administration of 500 mg of vitamin
C per day for 50 days from the date of the injury reduces
the incidence of CRPS-I in patients with wrist fractures
(level 2: Zollinger et al. (A2), Cazeneuve et al. (B)).
Guanethidine
In a randomized study (n = 71), patients scheduled for
surgery for Dupuytren's disease were referred for pre-
emptive intravenous guanethidine blockade or a placebo
blockade. After eight weeks 13% of the patients taking
guanethidine were found to have developed CRPS-I, as
against 6% in the control group [96].
There are no indications that perioperative intravenous
guanethidine in patients undergoing fasciectomy for
Dupuytren's disease has any effect on the incidence of
CRPS-I (level 3: Gschwind et al. (A2)).
Calcitonin
In a double blind randomized study, 91 patients undergo-
ing wrist, knee or foot surgery were treated with for 100
IU of thyrocalcitonin administered subcutaneously (from
the day of the operation or the trauma once a day for one
week and three times a week for three weeks thereafter)
or placebo injections. No significant differences were
found between placebo and thyrocalcitonin in reducing
the occurrence of CRPS-I [97].
There are no indications that subcutaneous administra-
tion of calcitonin for four weeks from the onset of the
trauma or from the date of surgery can prevent patients
developing CRPS-I (primary prevention) (level 3: Riou et
al. (B)).
Secondary prevention
Various interventions or combinations of interventions
aimed at preventing relapse of CRPS-I have been
described, but little adequate research has been carried
out. Relapse rates up to 13% (of 47 patients) have been
reported despite combined interventions aimed at pre-
venting relapse of CRPS-I (waiting until the symptoms of
CRPS-I had abated, minimizing the use of tourniquet,
administering vasodilators to encourage circulation, sym-
pathetic blockades and mannitol) [98]. Six percent of
patients with a history of CPRS-I (n = 18) treated with
calcitonin (100 IU a day s.c. for four weeks) had a relapse
of CRPS-I, against 28% of the patients in a historic con-
trol group (n = 74) [99]. A retrospective study (n = 50)
found that peri-operative stellate ganglion blockade car-
ried out to prevent a relapse of CRPS-I to be unsuccessful
in 10% of cases. The relapse rate in an untreated control
group was 72% [100].
A retrospective study (n = 1200) found that 1% of the
patients undergoing anterior cruciate ligament surgery
receiving pre-emptive analgesia (comprising administra-
tion of paracetamol and NSAIDs before surgery) com-
bined with multimodal analgesia experienced a relapse of
CPRS-I. The CRPS-I relapse rate for a control group, tak-
ing painkillers only as required after surgery, was 4%
[101].
In a randomized double-blind study in 84 patients with
a history of CRPS-I in the hand or arm scheduled for
hand or arm surgery, intravenous regional blockade with
lidocaine and clonidine (1 μg/kg) showed a relapse rate
for clonidine of 10% against 74% in the group receiving
only lidocaine [100]. Case studies point to a possible ben-
eficial effect of regional anaesthesia, such as brachial
plexus block and epidural anaesthesia [101].
Despite lack of evidence, the task force is of the opinion
that operations are preferably postponed until CRPS-I
signs are minimal. Preferably, regional anaesthetic tech-
niques such as brachial plexus blockade and epidural
anaesthesia should be used (level 4)
There are indications that stellate blocks and intrave-
nous regional anaesthesia using clonidine (not guanethi-
dine) offer protection (level 3: Reuben et al. (A2)).
There are indications that the use of multimodal anal-
gesia offers protection (level 3: Reuben (A2).
There are indications that daily administration of 100
IU of salmon calcitonin s.c. (peri-operatively for four
weeks) can prevent a relapse of CRPS-I (level 3: Kissling et
al. (B)).
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Besides scientific evidence, other aspects are important
in the formulation of guidelines, such as patient perspec-
tives, availability of special techniques or expertise,
organisational aspects, social consequences and costs.
For the present guidelines these considerations were for a
part based on Dutch perspectives. The conclusions based
on scientific publications were set into the context of
daily practice, and advantages and disadvantages of the
various possible policies considered. The final recom-
mendations are the result of the evidence available in
combination with these considerations. This procedure
followed in the present guideline development provides
the opportunity to incorporate the debate between proj-
ect group members in the formulation of recommenda-
tions, in order to make the guideline transparent and
bring the recommendations in line with general practice.
Based on the presented evidence based evaluation of
CRPS-I literature, in combination with additional consid-
erations with regard to availability of treatment methods,
side-effects, cost-benefits and consequences for organisa-
tion of care, recommendations endorsed by the partici-
pating professional societies were formulated, described
additional file 3. In addition to these guidelines the task
force is of the opinion that regular consultation between
practitioners is desirable in order to provide uniform and
clear information to the patient. In line with these obser-
vations, the task force advocates that patients should be
actively informed about CRPS-I and possible conse-
quences of this complaint, whereby verbal as well as writ-
ten information should be provided. Although there is no
evidence of for specific psychological profile or predispo-
sition for patients with CRPS-I, there may be reasons to
carry out further psychological investigation. Possible
psychological factors maintaining and/or aggravating the
syndrome need to be determined.
A limitation of the guidelines presented in this article is
that only articles published up to 2006 were included, and
possible relevant findings published after this date
couldn't be incorporated in the present guidelines as a
consequence of the formal procedure (see method sec-
tion), involving the approval of participating professional
societies. An additional search based on the search string
used for these guidelines, revealed 45 additional articles
[108-152], possibly providing information that could lead
to amendment of this guideline. These articles comprised
one retrospective chart review [121], one prospective
cohort [120], six case series [117,125,127,128,132,133], 14
clinical trials
[109,111,112,119,122,123,126,131,135,138,140,146,147,15
0], two controlled clinical trials [130,136], 16 RCT's
[108,113,114,116,124,129,134,137,139,141,143,145,146,14
8,149,152], four systematic reviews/meta analyses
[110,115,142,144], and one treatment guideline [118].
Interventions evaluated therein were piroxicam [114],
gabapentin [126], intrathecal baclofen [146], sympathetic
blockade (lumbar, stellate ganglion and intravenous) (n =
5) [122,123,134,143,149], corticosteroids (n = 3)
[114,119,135], calcium regulating medication (bisphos-
phonates, calcitonin) (n = 4) [110,116,138,142], NMDA
antagonists (magnesium sulphate, ketamine, meman-
tine) (n = 9) [111,121,125,131,140,146-148,152], free radi-
cal scavengers (mannitol, vitamin C) (n = 3)
[129,135.137], nitric oxide regulating medication (n = 3)
[133,141,151], spinal cord stimulation (n = 5)
[112,115,120,128,132], regional anaesthesia (n = 2)
[113,117], physiotherapy and rehabilitation medicine
(physiotherapy, mirror therapy, manual lymph drainage,
vibratory stimulation, functional restoration, sensorimo-
tor retuning, behavioural therapy, occlusional splints) (n
= 11) [108,109,124,126,127,130,136,139,144,145,150]. Fif-
teen studies evaluated a combination of interventions,
and four controlled studies used an active control. Two
studies addressed primary prevention of CRPS I
[117,129]. These studies will have to be evaluated in the
next formal adaptation of these guidelines. In addition,
since the publication of these guidelines information pro-
vided in two studies included in these guidelines
[100,101] has been retracted due to scientific misconduct
of the author. Recommendations based on these data (i.e.
secondary prevention using pre-, per- and postoperative
pain control and regional blockades with clonidine)
therefore have to be regarded with caution.
Based on the identified literature and the extent of evi-
dence found therein for therapeutic interventions for
CRPS-I, we can conclude that further research is needed
into each of the modalities discussed in these guidelines.
This includes specifically treatment approaches recom-
mended (or not advised) in these guidelines based on
expert opinion, such as the use of botulin toxin and tricy-
clic antidepressants. Scientific data is also lacking with
respect to treatment-related aspects, such as the role of
the multidisciplinary approach, problems relating to
work and communication with the patient and his or her
family and close friends.
The project group considers that particular attention
needs to be paid to further development of the diagnostic
process. This development must be accompanied by
research into possible underlying pathophysiological
mechanisms (such as genetic factors) associated with
CRPS-I, with particular attention being paid to possible
sub-groups of the condition related to these underlying
mechanisms.
With regard to drug treatment, further investigation is
needed into the efficacy of pain medication and the per-
cutaneous sympathetic blockade. More research is also
needed into the use of drugs and invasive treatment with
children suffering from CRPS-I.
Perez et al. BMC Neurology 2010, 10:20
http://www.biomedcentral.com/1471-2377/10/20
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be placed on the difference between pain contingent and
a time contingent approach. Research is needed into the
effects of various interventions on more long-standing
(chronic) CRPS-I and into a multidisciplinary approach
to CRPS-I.
Conclusions
For pain treatment, the WHO analgesic ladder is advised
with the exception of strong opioids. For neuropathic
pain, anticonvulsants and tricyclic antidepressants may
be considered. For inflammatory symptoms, free-radical
scavengers (dimethylsulphoxide or acetylcysteine) are
advised. To promote peripheral blood flow, vasodilatory
medication may be considered. Percutaneous sympa-
thetic blockades may be used to increase blood flow in
case vasodilatory medication has insufficient effect. To
decrease functional limitations, standardised physiother-
apy and occupational therapy are advised. To prevent the
occurrence of CRPS-I after wrist fractures, vitamin C is
recommended. Adequate perioperative analgesia, limita-
tion of operating time, limited use of tourniquet, and use
of regional anaesthetic techniques are recommended for
secondary prevention of CRPS-I.
Based on the literature identified and the extent of evi-
dence found for therapeutic interventions for CRPS-I, we
conclude that further research is needed into each of the
therapeutic modalities discussed in the guidelines.
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